1. Esketamine, which will be sold by Johnson & Johnson under the brand name Spravato, is a nasal spray to treat intractable depression. It is controversial due to its potential for abuse.
2. Rivastigmine Transdermal System was approved for the treatment of dementia associated with Alzheimer’s and Parkinson’s disease.
3. Imatinib Mesylate tablets, known by the brand name Stason, is a generic form of Novartis’ Gleevec tablets. The chemotherapy drug slows the growth of cancer cells.
4. Glenmark Pharmaceuticals received final FDA approval for its generic version of Boehringer Ingelheim’s Micardis HCT Tablets. The new generic, telmisartan and hydrochlorothiazide, treats high blood pressure.
More articles on supply chain:
Supplies of bladder cancer drug are dwindling
Washington faces critically low blood supply
Supply chain savings tip of the week: Manage your total transportation spend
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
